Explore more publications!

Health Reporter French Polynesia: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Reporter French Polynesia.

Press releases published on November 4, 2025

Sight Sciences to Present at Two Upcoming Investor Conferences
Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
Standard BioTools Reports Third Quarter 2025 Financial Results
Ceribell Reports Third Quarter 2025 Financial Results
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
ImmuCell Announces Onboarding of New CEO and Related Management Changes
OnKure Therapeutics to Participate in Upcoming Investor Conferences
OrthoPediatrics to Participate in Upcoming Conferences
Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2025
Clover Health Reports Third Quarter 2025 Results
Amwell® Announces Results for Third Quarter 2025
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solana Company Files Application to Cease to Be a Reporting Issuer in Canada
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions